Is HCA Healthcare Stock Underperforming the Nasdaq?

HCA Healthcare, headquartered in Nashville, Tennessee, is a large-cap company valued at $87 billion, specializing in healthcare services and education. The company has a diversified portfolio, attracting patients in high-growth states like Florida, Texas, and Tennessee. Despite its market leadership, HCA's stock has underperformed the Nasdaq Composite index over the past year, slipping 27% from its 52-week high.

The decline can be attributed to a worsening payer mix, as many individuals lost coverage through health insurance exchanges following the expiration of Affordable Care Act subsidies. This shift towards uninsured or underinsured patients led to a decline in high-margin surgeries, negatively impacting reimbursement rates. While HCA stock has fallen 13.2% year-to-date, the Nasdaq Composite has gained 1.6%.

HCA's management has already revised its full-year EPS guidance downwards, to a range of $28.70 to $30.50. Despite these challenges, Wall Street analysts remain cautiously optimistic about HCA's future, giving the stock a "Moderate Buy" rating and a mean price target of $455.05, representing a potential 12% upside from current levels.